胎儿生长限制:指导分娩时间和产后管理的当代证据
Ana Carolina Rabachini Caetano1, Ana Cristina Perez Zamarian1, Luciano Marcondes Machado Nardozza1
1Department of Obstetrics, Paulista School of Medicine, Federal University of São Paulo (EPM-UNIFESP), São Paulo 04023-062, SP, Brazil.
Diagnostics (Basel, Switzerland)
|March 14, 2026
概括
胎儿生长限制 (FGR) 管理需要根据胎儿的健康状况和妊娠年龄,仔细安排分娩时间. 证据指导临床医生在FGR怀孕的分娩方法,尽管有限的随机试验.
科学领域:
- 产科和妇科 产科和妇科
- 围产儿医学 围产儿医学
- 胎儿医学 胎儿医学
背景情况:
- 胎儿生长限制 (FGR) 影响5-10%的怀孕,增加围产期发病率和死亡率.
- 目前关于最佳FGR诊断和管理的证据有限.
- 2016年的共识旨在标准化FGR术语和诊断.
研究的目的:
- 更新有关FGR复杂妊娠的最佳时间和方法的证据.
- 强调胎儿监测异常如何引导不同妊娠年龄的分娩决策.
主要方法:
- 在PubMed/Medline和LILACS数据库的文献搜索 (过去10年).
- 关键词:胎儿生长限制,管理,分娩.
- 结果按分娩时的妊娠年龄,分娩方式和分娩诱导方法分类.
主要成果:
- 特定的胎儿监测异常需要在不同的妊娠年龄分娩.
- 基于证据开发了管理流程图.
- 尽管随机试验有限,但可用的证据被总结为临床指导.
结论:
- 最佳的FGR怀孕管理取决于平衡早产风险与胎儿后果或死亡风险.
- 胎儿监测结果对于确定FGR的分娩时间至关重要.
- 需要进一步进行高质量的研究,包括随机临床试验,以完善FGR管理策略.
相关概念视频
Intrauterine Drug Delivery Systems
100
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
100
Teratogenicity
4.4K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
4.4K


